10.7. Analysis.

Comparison 10 Patient reports/series: number of participants with non‐serious adverse events, Outcome 7 Gastrointestinal system.

Gastrointestinal system
Study
Loss of appetite
Agarwal 2008	A case report of the combination of atomoxetine and methylphenidate treatment of ADHD. Non‐serious adverse events: decreased appetite and delayed onset in sleep
Coşkun 2009a	IR MPH, 10–20 mg/day, co‐medication: valproate 400 mg/day. Decreased appetite, no weight decrease
Ghanizadeh 2008a	A case report of decrease in appetite during treatment with MPH
Rappaport 2004	A case report of side effects during MPH treatment in a 14‐year‐old boy with ADHD and a number of other co‐morbid conditions (whilst taking immediate‐release MPH)
Yalcin 2012	Significant appetite loss, drowsiness, disturbance of voice and hoarseness Disturbance of voice and hoarseness occurred on everyday since the first day of the medication. The symptoms started short after the single morning dose and decreased gradually to dinner time and disappeared before bedtime. Drug‐free days: no symptoms. Otolaryngology consultation: no organic pathology was detected with respect to clinical and endoscopic observation. Discontinuation of MPH and prescription of atomoxetine: no symptom of hoarseness and disturbance of voice quality
Nausea and vomiting
Rappaport 2004	A case report of side effects during MPH treatment in a 14‐year‐old boy with ADHD and a number of other co‐morbid conditions (whilst taking extended‐release MPH: Concerta)